Vedanta Granted U.S. Patent
News Aug 25, 2016
Vedanta Biosciences has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,415,079. The patent broadly covers pharmaceutical compositions and mixtures of Clostridium live bacterial strains and builds on Vedanta’s patent issuances in Japan. The issued patent is exclusively licensed worldwide to Vedanta under an agreement with the University of Tokyo and provides coverage through at least 2031.
The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta. Dr. Honda’s work provides an avenue for the treatment of a variety of diseases including immune and infectious diseases employing bacterial strains belonging to Clostridium clusters IV and/or XIVa. Clostridium bacteria include a variety of spore-forming species that can abundantly colonize the gut.
“We believe this issuance puts Vedanta in an IP leadership position in the microbiome field,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta. “The patent has broad, fundamental claims that we believe will be important for the commercialization of microbiome therapeutics based on bacterial consortia. We intend to continue to build value from our IP estate through our internal programs as well as alliances with pharmaceutical partners.”
Controlling mosquito-borne illnesses has historically been difficult. Scientists have turned to manipulating Wolbachia, a parasitic bacterium within mosquitoes, as a way to control the reproductive fitness of mosquito populations that transmit human disease. In a study, researchers identified a new mobile DNA element in Wolbachia, which may contribute to improved control strategies for mosquito vectors of disease.